GORE VIATORR? TIPS ENDOPROSTHESIS

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,litera report with the FDA on 2017-04-20 for GORE VIATORR? TIPS ENDOPROSTHESIS manufactured by W.l. Gore & Associates.

Event Text Entries

[73230949] (b)(6). (b)(4). Date of event: the date when the article was published was used as event date.
Patient Sequence No: 1, Text Type: N, H10


[73230950] This information was received through literature article? Endovascular removal of the viatorr stent-grafts. Report of two cases? Published: 22 may 2015 in polish journal of radiology. Cwikiel, wojciech, bergenfeldt, magnus, keussen, inger. Endovascular removal of the viatorr stent-grafts. Report of two cases. Polish journal of radiology. 2015; 80:277-80 issn: 1733-134x, 1733-134x (issnlinking). Second case: the article stated that a (b)(6) male with alcohol-related cirrhosis, ascites and bleeding from the varices was referred for gore? Viatorr? Tips endoprosthesis to the department of endovascular surgery of a nearby hospital. Co2 portography was performed in there through a balloon catheter placed in the branch of the middle hepatic vein, showing patent pv. During transjugular, transhepatic attempt to puncture pv, a bile duct was accidentally entered (figure 3). That was misinterpreted by the physician performing the procedure, who placed a viatorr connecting the bile duct to the right hepatic vein. The physician reported later that? The flow from the smv was good, the gradient was=0 mmhg, and the tips was created successfully?. On the following three days the patient? S condition deteriorated and on the fourth day he showed signs of general sepsis and abdominal distension requiring urgent icu care. The inflammatory parameters were high and the laboratory tests were critically elevated (p-bilirubin=466? Mol/l;crp=43 mg/l; p-creatinine=435? Mol/l). At that time the error was identified and a percutaneous biliary drainage catheter was placed percutaneously through the right liver lobe bile ducts to the duodenum. Afterwards, the patient was transferred to the department of hepatic surgery for urgent treatment. The first viatorr was removed and a second viatorr was placed successful. Co2 portography confirmed good flow through the tips channel and no flow to the bile duct. In the following three weeks, the patient recovered substantially and the laboratory test results normalized.
Patient Sequence No: 1, Text Type: D, B5


[74292206]
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number3007284313-2017-00098
MDR Report Key6506952
Report SourceCOMPANY REPRESENTATIVE,LITERA
Date Received2017-04-20
Date of Report2017-04-25
Date of Event2015-05-22
Date Added to Maude2017-04-20
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactRUTH KUNZMANN
Manufacturer Street1500 N. 4TH STREET
Manufacturer CityFLAGSTAFF AZ
Manufacturer Phone9285263030
Manufacturer G1MEDICAL PHOENIX 1 B/P
Manufacturer Street32360 N. NORTH VALLEY PARKWAY
Manufacturer CityPHOENIX AZ 85085
Manufacturer CountryUS
Manufacturer Postal Code85085
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameGORE VIATORR? TIPS ENDOPROSTHESIS
Generic NameSHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS
Product CodeMIR
Date Received2017-04-20
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerW.L. GORE & ASSOCIATES
Manufacturer AddressFLAGSTAFF AZ


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization; 2. Required No Informationntervention 2017-04-20

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.